The Saudi Food and Drug Authority (SFDA) has launched the “Nader” program under its regulatory framework for rare disease medicines, aiming to support the development and registration of treatments for rare diseases and accelerate patients’ access to promising therapies.
The initiative is part of the authority’s efforts to strengthen the regulatory environment for researchers and innovators and provide scientific and regulatory incentives that can facilitate the development of new pharmaceutical solutions, particularly in areas where limited patient populations create challenges for conventional clinical development.
Which diseases does the “Nader” program cover?
According to the SFDA, the program covers medicines intended to treat or prevent rare diseases with a prevalence of fewer than five cases per 10,000 people in Saudi Arabia.
Eligible products must either address a condition for which no effective treatment is available or provide a therapeutic benefit beyond existing treatment options. The medicine must also either be under development or have been approved by another regulatory authority without being registered in Saudi Arabia.
Scientific and regulatory incentives
The “Nader” program provides a package of incentives and facilitations designed to address some of the challenges involved in developing medicines for rare diseases.
These measures include scientific and regulatory support for developers and relevant stakeholders, as well as flexible and innovative approaches to generating scientific evidence that take into account the limited number of patients associated with rare diseases.
The program also includes flexible procedures for registering manufacturing facilities and support for periodic safety-reporting requirements, helping developers navigate regulatory requirements while advancing promising treatments.
Supporting researchers and pharmaceutical innovation
The initiative is not limited to accelerating patient access to medicines. It also aims to empower researchers and innovators to develop new solutions for rare diseases.
By creating a more supportive regulatory pathway for these medicines, the program is expected to contribute to pharmaceutical innovation and improve opportunities for patients whose existing treatment options may be limited.
Supporting Saudi Vision 2030
The launch of the “Nader” program forms part of the SFDA’s broader efforts to provide integrated healthcare and enable patients to access promising treatments, in line with Saudi Vision 2030 objectives focused on improving quality of life and advancing the Kingdom’s healthcare system.
The program reflects a regulatory approach designed to accommodate the specific challenges of rare disease medicines while maintaining the scientific and regulatory requirements needed to support their safety and effectiveness.
